CureVac Expands CVnCoV Covid-19 Vaccine Candidate Clinical Trial Analyses to Include Phase 3 Variant Specification and Efficacy Secondary Endpoint to Phase 2a Impact of new SARS-CoV-2 variants supports specification of s

CureVac Expands CVnCoV Covid-19

Vaccine Candidate Clinical Trial Analyses to Include

Phase 3 Variant Specification and Efficacy Secondary Endpoint to Phase 2a

T BINGEN, Germany/ BOSTON,

USA - March 22, 2021 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class

of transformative medicines based on messenger ribonucleic acid (mRNA), today announced plans to expand and further specify the

protocols of its ongoing late-stage clinical trials with CVnCoV, its COVID-19 vaccine candidate.

CVnCoV efficacy is currently

being evaluated in the pivotal HERALD Phase 2b/3 trial in Europe and Latin America. Rapid distribution of new virus variants in

the countries where the study is conducted supports the need for further analysis specification for the anticipated case-driven

interim analysis. This will allow to determine efficacy of the vaccine candidate for select variants. The company has ongoing

discussions with the European Medicines Agency (EMA) to potentially include an amendment related to select virus strains in the

For its Phase 2a dose-confirmation

trial in older adults in Peru and Panama, CureVac has submitted a protocol amendment to include a secondary objective for vaccine

efficacy. The study initially aimed to evaluate safety, reactogenicity and immunogenicity of CVnCoV in adults. Expanded trial

analysis is expected to allow for collection of relevant efficacy data which includes the important group of approximately 270

participants above the age of 60, treated with 12 g of CVnCoV.

"Our goal is to offer the

public and especially the vulnerable older age groups the best possible protection against the virus and its variants with our

vaccine candidate", said Ulrike Gnad-Vogt, Interim Chief Development Officer of CureVac. "The additional efficacy

analysis in Phase 2a is intended to leverage the data we can collect from older adults, and will represent important complementary

data to the statistically relevant efficacy data from our HERALD trial. At the same time we need to make sure that our efficacy

data are meaningful in view of the emergence of new virus variants. We are therefore aiming to specify what type of virus we are

dealing with in the HERALD trial."

expects data readouts from both clinical trials in the second quarter 2021. It also reaffirms its intention to file for formal

marketing authorization within the second quarter 2021.

began development of its mRNA-based COVID-19 vaccine candidates in January 2020. The vaccine candidate chosen first for clinical

development, CVnCoV, is an optimized, non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein

of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles (LNPs). Phase 1 and 2a clinical trials of CVnCoV began in June

and September 2020, respectively. Phase 1 interim data reported in November 2020 showed that CVnCoV was generally well tolerated

across all tested doses and induced strong antibody responses in addition to first indication of T cell activation. The quality

of immune response was comparable to recovered COVID-19 patients, closely mimicking the immune response after natural COVID-19

infection. In December 2020 CureVac initiated a pivotal Phase 2b/3, the HERALD study, with a 12 g dose of CVnCoV. In February

2021 CureVac initiated a rolling submission with the European Medicines Agency (EMA) for CVnCoV.

has entered into several strategic partnerships for the further development, production and commercialization of CVnCoV. The company

signed a collaboration agreement with Bayer in January 2021 with regards to CureVac s current vaccine candidate CVnCoV.

In February 2021 CureVac and the British pharmaceutical company GlaxoSmithKline (GSK) agreed to jointly develop next-generation

multi-valent mRNA vaccines against COVID-19. The development of new vaccine candidates is strengthened by a partnership with the

UK Government and its Vaccines Taskforce, which CureVac also entered in February 2021. GSK will also potentially contribute to

this collaboration. Clinical trial and commercial material is provided by the company's substantial production capacities

for mRNA vaccines at its headquarters in T bingen, supported by the current expansion of manufacturing capacities in Europe,

allowing broad-scale manufacturing of CVnCoV for potential commercial supply preparedness.

the Phase 2a Clinical Trial

started its Phase 2a Clinical Trial with CVnCoV at the end of September 2020. The dose-confirmation study has been conducted in

Peru and Panama and enrolled a total of 670 participants in two distinct groups: older adults ages 61 and above, and younger participants

18 to 60 years old. The participants received two vaccinations at intervals of 28 days with the aim to evaluate safety, reactogenicity

and immunogenicity in healthy adults.

is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in

developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology

is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of

fighting a broad range of diseases. Based on its proprietary technology, the Company has built a deep clinical pipeline across

the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its

initial public offering on the New York Nasdaq in August 2020. It is headquartered in T bingen, Germany, and employs more

than 600 people at its sites in T bingen, Frankfurt, and Boston, USA. Further information can be found at www.curevac.com.

CureVac Media Contact

Thorsten Sch ller, Vice

President Communications

CureVac, T bingen, Germany

T: +49 7071 9883-1577

CureVac Investor Relations

Dr. Sarah Fakih, Vice President

CureVac, T bingen, Germany

T: +49 7071 9883-1298

M: +49 160 90 496949

Forward-Looking Statements

This press release contains statements

that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation

Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections

of CureVac (the "company") regarding future events or future results, in contrast with statements that reflect historical

facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's

strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements

by terminology such as "anticipate," "intend," "believe," "estimate," "plan,"

"seek," "project," or "expect," "may," "will," "would,"

"could," "potential," "intend," or "should," the negative of these terms or similar

expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently

available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and

you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and

other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide

financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the

timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize

products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental

policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19

pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance

on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect

of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned

not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause

its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press

release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update

any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments,

except as required by law.

information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission

(SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov